The safety profile of biologic therapies for juvenile idiopathic arthritis.
The treatment of juvenile idiopathic arthritis (JIA) has been revolutionized by the use of novel biologic agents that have much improved patients' short-term and, according to early evidence, long-term outcomes. Currently available biologic agents used to treat patients with JIA include tumor necrosis factor (TNF) blockers, various agents that target interleukin (IL)-1 and the IL-6 receptor, T-cell co-stimulation inhibitors and antibodies to B-lymphocyte antigen CD20. These agents are increasingly used early in the course of the disease (often in combination with other immunosuppressive medications) and often for long periods of time, as patients can be difficult to wean from their use. Safety concerns (especially the long-term effects of biologic therapy) are, therefore, being examined more closely. For instance, in 2009, the FDA issued a warning related to the development of malignancies in patients with JIA who had used anti-TNF medications for >2.5 years. In this Review, data related to the safety profile of all currently available biologic agents used to treat JIA are examined, with a particular focus on anti-TNF therapy, the most studied biologic agent for JIA. Safety issues that need further study, including the implementation of registries to monitor long-term drug safety, are also discussed.
Hashkes
Philip J
PJ
Pediatric Rheumatology Unit, Department of Pediatrics, Shaare Zedek Medical Center, Jerusalem 91031, Israel. hashkesp@szmc.org.il
Uziel
Yosef
Y
Laxer
Ronald M
RM
D000293:Adolescent; D016907:Adverse Drug Reaction Reporting Systems; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D001691:Biological Therapy / Q000009:adverse effects*; D002648:Child; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha
Rheumatol Int. 2010 Apr;30(6):801-4
19506877
Clin Exp Rheumatol. 2007 Jan-Feb;25(1):119
17418007
Ann Rheum Dis. 2003 Mar;62(3):245-7
12594111
Arthritis Rheum. 2003 Apr;48(4):1093-101
12687553
Ann Rheum Dis. 2010 Apr;69(4):718-22
20237125
Pediatr Clin North Am. 1995 Oct;42(5):1099-125
7567188
JAMA. 2005 Oct 5;294(13):1671-84
16204667
Ann Rheum Dis. 2009 Apr;68(4):519-25
18413440
Biologics. 2009;3:127-39
19707402
J Rheumatol. 2007 Dec;34(12):2503-4
18061971
J Clin Rheumatol. 2008 Oct;14(5):297-8
18824922
J AAPOS. 2006 Feb;10(1):26-9
16527676
Arthritis Rheum. 2010 Jun;62(6):1792-802
20191582
Ann Rheum Dis. 2009 Apr;68(4):552-7
18467515
Am J Ophthalmol. 2009 Nov;148(5):696-703.e1
19664754
Rheumatol Int. 2007 Dec;28(2):153-6
17641897
Rheumatology (Oxford). 2004 Apr;43(4):527-9
15024141
Arthritis Rheum. 2010 Aug;62(8):2517-24
20506368
N Engl J Med. 2008 Aug 21;359(8):810-20
18716298
Arthritis Rheum. 2013 Sep;65(9):2486-96
23754188
J Rheumatol. 2008 Aug;35(8):1681
18671329
J Clin Rheumatol. 2009 Jun;15(4):161-4
19363453
Arthritis Rheum. 2005 Feb 15;53(1):18-23
15696578
J Rheumatol. 2001 Jul;28(7):1677-80
11469478
Arthritis Rheum. 2001 Dec;44(12):2862-9
11762947
Ann Rheum Dis. 2009 Dec;68(12):1863-9
19147611
Biologics. 2008 Dec;2(4):865-74
19707464
Arthritis Rheum. 2010 Feb;62(2):599-608
20112378
J Rheumatol. 2008 Aug;35(8):1680-1
18671328
Arthritis Rheum. 2000 Nov;43(11):2606-8
11083287
J Rheumatol Suppl. 1992 Apr;33:6-10
1593604
Arthritis Rheum. 2002 Oct;46(10):2565-70
12384912
Arthritis Care Res (Hoboken). 2010 Nov;62(11):1542-51
20597110
Cytokine. 2008 Jun;42(3):293-7
18445529
Arthritis Rheum. 2006 Jun;54(6):1987-94
16732547
Arthritis Rheum. 2003 Jan;48(1):218-26
12528122
Ann Rheum Dis. 2008 Aug;67(8):1145-52
17981916
Arthritis Rheum. 2008 Jun 15;59(6):762-84
18512708
Ann Rheum Dis. 2004 Dec;63(12):1638-44
15115709
Clin Exp Rheumatol. 2003 Sep-Oct;21(5):645-6
14611117
Clin Exp Rheumatol. 2003 Mar-Apr;21(2):276-7
12747299
Ann Rheum Dis. 2009 May;68(5):635-41
18413443
Ann Rheum Dis. 2009 Jul;68(7):1228-9
19525408
J Rheumatol. 2003 Feb;30(2):401-3
12563702
Rheumatology (Oxford). 2009 Aug;48(8):916-9
19483091
Rheumatol Int. 2008 Aug;28(10):1031-4
18369626
Acta Reumatol Port. 2007 Apr-Jun;32(2):139-50
17572652
Arthritis Rheum. 2007 Sep;56(9):3096-106
17763439
N Engl J Med. 2000 Mar 16;342(11):763-9
10717011
Ann Rheum Dis. 2009 Apr;68(4):607-8
19286909
J Rheumatol. 2005 May;32(5):935-42
15868633
Lancet. 2008 Aug 2;372(9636):383-91
18632147
Rheum Dis Clin North Am. 1991 Nov;17(4):891-905
1767079
Rheumatology (Oxford). 2009 Apr;48(4):445-6
19164423
J Pediatr. 2006 Dec;149(6):833-6
17137902
Arthritis Res Ther. 2005;7(6):R1281-8
16277681
Lancet. 2008 Mar 22;371(9617):998-1006
18358927
Rheumatology (Oxford). 2006 Nov;45(11):1448-9
16920752
Ann Rheum Dis. 2006 Sep;65(9):1259
16905590
Rheumatology (Oxford). 2002 Dec;41(12):1450-2
12468829
Arthritis Rheum. 2008 May;58(5):1496-504
18438876
J Pediatr Gastroenterol Nutr. 2004 Aug;39(2):203-6
15269630
Ann Rheum Dis. 2008 Mar;67(3):302-8
17947302
Clin Rheumatol. 2009 Feb;28(2):129-37
18766426
Arthritis Rheum. 2009 Sep;60(9):2794-804
19714630